Allogene Therapeutics (ALLO)
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the tre...
- Open
- 1.970
- High
- 2.010
- Low
- 1.950
- Prev. Close
- 1.980
- Volume
- 4.43M
- Turnover
- 8.78M
- Avg Price
- 1.983
- Bid/Ask Ratio
- --
- Amplitude
- 3.03%
- 52wk High
- 4.460
- Volume Ratio
- 0.84
- Turnover Ratio
- 1.61%
Allogene Therapeutics Analyst Rating
View moreForecast & Rating
Aug 31, 2026Price forecast
$9.00356.85%
Forecast & RatingStrong buy
12analysts
- Strong buy66.67%
- Buy25.00%
- Hold8.33%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 2 days ago, 08:48 AM
701,901 Shares in Allogene Therapeutics, Inc. $ALLO Acquired by Man Group plc
- Tip Ranks · Sep 2 at 01:26 PM
Allogene Therapeutics Announces Retirement of Chief Financial Officer
- PUBT · Aug 31 at 12:30 PM
Allogene Therapeutics to present at Citi Biopharma Back to School Conference
